logo-loader
viewArtios Pharma Ltd

Artios in strong position to accelerate cancer programmes after Arix investment

Proactive Investors' Andrew Scott sits down with Arix Bioscience Plc's (LON:ARIX) investment director Jonathan Tobin and Niall Martin, chief executive of Artios Pharma.

Arix has recently upped its stake in Artios following a Series B financing round that was backed by the venture capital arms of industry giants Pfizer and Novartis.

Artios Pharma's developing DNA damage response technology to treat cancer.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Ariana Resources' Kerim Sener talks 'continued positive performance' at...

Ariana Resources PLC's (LON:AAU) Kerim Sener says the firm's enjoyed one its strongest quarters ever for revenues generated. He says production from the Kiziltepe mine in Turkey was just shy of 7,000oz and combined with a very strong gold price boosted sales. Sener also updates on...

35 minutes ago

2 min read